News and Events
Alzheimer’s Breakthrough: C₂N First to Offer a Widely Accessible Blood Test
A breakthrough in Alzheimer’s disease has arrived with C2N Diagnostics’ PrecivityAD™ blood test into the clinic. The PrecivityAD™ test is a highly sensitive Alzheimer’s blood test using mass spectrometry and is performed in a CLIA-certified lab. The PrecivityAD™ test is easy to administer, does not involve any radiation, and is non-invasive. These features are expected to make the test more accessible than other diagnostic methods that physicians use to evaluate issues with memory and thinking.
ADDF Announces Major Funding Commitment to Validate an Amyloid Blood Test for Non-Invasive Early Detection of Alzheimer’s
C₂N Diagnostics has been awarded more than $2.2 million to accelerate clinical validation and accreditation of its beta-amyloid blood test.
Identification of p-tau217 in Blood Samples Offers Early Detection of Alzheimer’s Disease and Builds Interest in C₂N Intellectual Property
Brain protein tau phosphorylated at position 217 (p-tau217) is measurable in blood by mass spectrometry and that this form of tau is a powerful early indicator of Alzheimer’s disease.
C₂N Diagnostics Reports High Accuracy of PrecivityAD™ Blood Test for Detecting Early Alzheimer’s Disease Pathology
PrecivityAD™ blood test showed high performance for identifying presence or absence of Alzheimer’s pathology in the brain.
